Selexipag

Selexipag Overview

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[1] ACT-333679 or MRE-269, the active metabolite of selexipag Contents 1 Contraindications 2 Adverse effects 3 History 4 See also 5 References Contraindications...

Read more Selexipag Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selexipag

Recent Selexipag Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Selexipag

Tablet: 0.2mg, 0.4mg, 0.6mg, 0.8mg, 1.2mg, 1.4mg, 1.6mg, 1000mcg, 1200mcg, 1400mcg, 1600mcg, 1mg, 200mcg, 400mcg, 600mcg, 800mcg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Selexipag: (1 result)

Sorted by National Drug Code

66215-628 Uptravi Titration Pack Kit by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Selexipag or a similar ingredient: (1 result)

UPTRAVI Selexipag